Abstract：
BACKGROUND: Oral finasteride and topical minoxidil are the current standard of care for male androgenetic alopecia and a combination of the two treatments can be considered for greater efficacy. Clinical trials of topical finasteride have also yielded promising results, but routine care data are lacking.
OBJECTIVE: To examine patient-reported outcomes of men with androgenetic alopecia who received topical finasteride admixed with minoxidil compared to the current standard of care (oral finasteride).
METHODS: Retrospective, cross-sectional study with data from a German direct-to-consumer teledermatology platform between December 2021 and January 2023. Patient-reported outcomes were collected through voluntary follow-up questionnaires provided after 6 weeks on topical finasteride/minoxidil or oral finasteride treatment.
RESULTS: A total of 1545 patients who received topical finasteride/minoxidil treatment were included; 238 (15.4%) participated in the follow-up questionnaire. At week six, 62.2% (148/238) reported positive changes in their hair appearance, and 44.1% (105/238) reported an improvement of self-esteem. Treatment-related adverse events were reported in 11.8% (28/238). Full treatment adherence was observed in 74.4% (177/238). Comparing the topical treatment group to those receiving oral finasteride, lower treatment adherence was reported, along with higher rates of local adverse events; no difference was found in the incidence of sexual adverse events.
CONCLUSIONS: Based on patient-reported outcomes, topical finasteride/minoxidil seems to be effective and well tolerated, but not superior to oral finasteride. Lower treatment adherence for topical usage must be considered when considering treatment options. Additional real-world data are needed to further evaluate the efficacy and safety of topical finasteride/minoxidil.
OBJECTIVE: To examine patient-reported outcomes of men with androgenetic alopecia who received topical finasteride admixed with minoxidil compared to the current standard of care (oral finasteride).
METHODS: Retrospective, cross-sectional study with data from a German direct-to-consumer teledermatology platform between December 2021 and January 2023. Patient-reported outcomes were collected through voluntary follow-up questionnaires provided after 6 weeks on topical finasteride/minoxidil or oral finasteride treatment.
RESULTS: A total of 1545 patients who received topical finasteride/minoxidil treatment were included; 238 (15.4%) participated in the follow-up questionnaire. At week six, 62.2% (148/238) reported positive changes in their hair appearance, and 44.1% (105/238) reported an improvement of self-esteem. Treatment-related adverse events were reported in 11.8% (28/238). Full treatment adherence was observed in 74.4% (177/238). Comparing the topical treatment group to those receiving oral finasteride, lower treatment adherence was reported, along with higher rates of local adverse events; no difference was found in the incidence of sexual adverse events.
CONCLUSIONS: Based on patient-reported outcomes, topical finasteride/minoxidil seems to be effective and well tolerated, but not superior to oral finasteride. Lower treatment adherence for topical usage must be considered when considering treatment options. Additional real-world data are needed to further evaluate the efficacy and safety of topical finasteride/minoxidil.
摘要：
背景：口服非那雄胺和外用米诺地尔是目前治疗男性雄激素性脱发的标准，两种治疗的组合可以被认为具有更大的疗效。局部非那雄胺的临床试验也取得了有希望的结果，但缺乏常规护理数据。
目的：与目前的治疗标准（口服非那雄胺）相比，观察接受局部非那雄胺与米诺地尔混合治疗的男性雄激素性脱发患者报告的结局。
方法：回顾性，在2021年12月至2023年1月期间，使用来自德国直接面向消费者的远程皮肤病学平台的数据进行的横断面研究。通过非那雄胺/米诺地尔或口服非那雄胺治疗6周后提供的自愿随访问卷收集患者报告的结果。
结果：共纳入1545例接受非那雄胺/米诺地尔局部治疗的患者；238例（15.4%）参加了随访问卷。第六周,62.2％（148/238）报告了头发外观的积极变化，44.1%(105/238)的人报告自尊有所改善。治疗相关的不良事件报告为11.8%(28/238)。在74.4%(177/238)中观察到完全的治疗依从性。比较局部治疗组与接受口服非那雄胺的治疗组，据报道治疗依从性较低，局部不良事件发生率较高;性不良事件发生率无差异.
结论：根据患者报告的结果，局部非那雄胺/米诺地尔似乎有效且耐受性良好，但不优于口服非那雄胺。在考虑治疗方案时，必须考虑局部使用的较低治疗依从性。需要其他实际数据来进一步评估非那雄胺/米诺地尔的疗效和安全性。
目的：与目前的治疗标准（口服非那雄胺）相比，观察接受局部非那雄胺与米诺地尔混合治疗的男性雄激素性脱发患者报告的结局。
方法：回顾性，在2021年12月至2023年1月期间，使用来自德国直接面向消费者的远程皮肤病学平台的数据进行的横断面研究。通过非那雄胺/米诺地尔或口服非那雄胺治疗6周后提供的自愿随访问卷收集患者报告的结果。
结果：共纳入1545例接受非那雄胺/米诺地尔局部治疗的患者；238例（15.4%）参加了随访问卷。第六周,62.2％（148/238）报告了头发外观的积极变化，44.1%(105/238)的人报告自尊有所改善。治疗相关的不良事件报告为11.8%(28/238)。在74.4%(177/238)中观察到完全的治疗依从性。比较局部治疗组与接受口服非那雄胺的治疗组，据报道治疗依从性较低，局部不良事件发生率较高;性不良事件发生率无差异.
结论：根据患者报告的结果，局部非那雄胺/米诺地尔似乎有效且耐受性良好，但不优于口服非那雄胺。在考虑治疗方案时，必须考虑局部使用的较低治疗依从性。需要其他实际数据来进一步评估非那雄胺/米诺地尔的疗效和安全性。
